Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Work In Process (2025)

Soleno Therapeutics (SLNO) has disclosed Work In Process for 1 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Work In Process changed N/A to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.7 million for FY2025, N/A changed from the prior year.
  • Work In Process for Q4 2025 was $2.7 million at Soleno Therapeutics, up from $2.0 million in the prior quarter.
  • The five-year high for Work In Process was $2.7 million in Q4 2025, with the low at $950000.0 in Q2 2025.